Treatment News : Treatment Interruptions May Still Have a Future

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » November 2008

Most Popular Links
Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


November 13, 2008

Treatment Interruptions May Still Have a Future

Temporarily stopping antiretroviral (ARV) therapy may turn out to be safe and advantageous in some circumstances, according to two studies presented at the Ninth International Congress on Drug Therapy in HIV Infection held in Glasgow and reported by AIDSmap.

Results from the Strategic Management of Antiretroviral Therapy (SMART) study have largely put the kibosh on the idea of HIV treatment breaks. The largest treatment interruption study conducted to date, SMART compared people who remained on continuous ARV therapy with people who either delayed or stopped treatment until their CD4 counts fell below 250 cells. In January 2006, the 5,500-patient study was stopped early because of more side effects, health complications and deaths among people who delayed or stopped treatment.

Data from the smaller LOTTI study, reported in Glasgow by Franco Maggiolo, MD, from the Ospital Riuniti in Bergamo, Italy, paint a more optimistic picture. In this clinical trial, where 329 HIV-positive people stopped and restarted treatment at higher CD4 counts than in SMART—700 cells and 350 cells, respectively—the rate of deaths and complications was similar among those who interrupted therapy and those who remained on continuous treatment.

The primary outcomes measured in the study were deaths, progression to AIDS or hospitalization for any reason. After an average of four years in the study, Dr. Maggiolo reported, 12 percent of those who took treatment breaks and 11 percent of those who remained on therapy reached one of these outcomes. People in the drug holiday group were able to remain off treatment 65 percent of the time, and people whose lowest-ever CD4 count was 500 were able to remain off treatment 85 percent of the time.

In direct contrast with SMART, there were actually 10 times as many cardiovascular and metabolic complications in the continuous therapy group in LOTTI than in the treatment break group. Maggiolo pointed to several possible explanations for the contradictory results. First, only 5 percent of patients in the LOTTI study ever had CD4 counts below 350 compared with 35 percent in SMART. Second, because SMART was stopped early, it may not have had enough time for cardiovascular and metabolic events to occur in the continuous treatment group.

A second treatment interruption study, presented by Cal Cohen, MD, from Harvard Medical School in Boston, tried a completely different approach. Called the FOTO study, for “Five On, Two Off,” this trial compared 42 people who stopped taking their meds for two days every weekend with people who remained on continuous therapy. All the patients took Sustiva (efavirenz) plus Truvada (tenofovir plus emtricitabine).

After 24 weeks, 83 percent of those who took treatment breaks had viral loads under 50 compared with 80 percent of those who remained on continuous treatment. Excluding study drop-outs—most left due to the intensive monitoring involved—100 percent of those who took treatment breaks had viral loads under 50, compared with 85 percent in the continuous treatment arm.

While there are still more data to be analyzed from LOTTI and FOTO, the authors of both studies suggest that treatment breaks may still have a future in HIV treatment, despite the results of SMART. This could be good news for people with HIV, who in the FOTO study overwhelmingly liked the option of taking a drug holiday every weekend.

Search: treatment interruption, break, drug holiday, SMART, LOTTI, FOTO, Franco Maggiolo, Cal Cohen, Sustiva, efavirenz, Truvada, tenofovir, emtricitabine

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (2 total)

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.